Case report EGFR Neuroendocrine Small cell lung cancer Spontaneous transformation

Journal

JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 09 10 2021
revised: 22 11 2021
accepted: 29 11 2021
entrez: 10 1 2022
pubmed: 11 1 2022
medline: 11 1 2022
Statut: epublish

Résumé

Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders the tumors unresponsive to EGFR tyrosine kinase inhibitors. Here, we present a case of spontaneous transformation from

Identifiants

pubmed: 35005656
doi: 10.1016/j.jtocrr.2021.100264
pii: S2666-3643(21)00123-5
pmc: PMC8718492
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100264

Informations de copyright

© 2021 The Authors.

Références

Nat Commun. 2015 Mar 11;6:6377
pubmed: 25758528
J Thorac Oncol. 2019 Jan;14(1):130-134
pubmed: 30217489
J Thorac Oncol. 2019 Oct;14(10):1784-1793
pubmed: 31228622
Elife. 2021 Jun 14;10:
pubmed: 34121659
Cancer Cell. 2011 Jun 14;19(6):754-64
pubmed: 21665149

Auteurs

Sho Takuma (S)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yusuke Inoue (Y)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Masato Karayama (M)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Kazuo Tsuchiya (K)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Hiroe Tsukui (H)

Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Hironao Hozumi (H)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yuzo Suzuki (Y)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Kazuki Furuhashi (K)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Noriyuki Enomoto (N)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Tomoyuki Fujisawa (T)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Yutaro Nakamura (Y)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Naoki Inui (N)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Takafumi Suda (T)

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Classifications MeSH